Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (101-110 of 247) with videos related to

Pageof 25
Sort By:
Clinical Colorectal Cancer|August 16, 2011
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancerDavid R Spigel, Johanna C Bendell, Michael McCleod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2007
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasCarol Aghajanian, Howard A Burris, Suzanne Jones, et al.
Current Drug Metabolism|April 6, 2012
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancerDan Lu, Howard A Burris, Bei Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2012
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, Mark S Rubin, et al.
Cancer Investigation|July 6, 2016
A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal TumorsJohanna C Bendell, Todd M Bauer, Ruth Lamar, et al.
Breast Cancer Research and Treatment|November 29, 2023
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancerErica L Mayer, Nabihah Tayob, Siyang Ren, et al.
The Oncologist|October 29, 2002
A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignanciesSuzanne F Jones, F Anthony Greco, John D Hainsworth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignanciesHoward A Burris, Charles W Taylor, Suzanne F Jones, et al.
Clinical Genitourinary Cancer|February 15, 2008
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trialJohn D Hainsworth, David R Spigel, Jeffrey A Sosman, et al.
Clinical Breast Cancer|January 15, 2020
A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast CancerDenise A Yardley, William Liggett, Mark Mainwaring, et al.
Pageof 25

Showing results (101-110 of 247) with videos related to

Sort By:
Pageof 25
Clinical Colorectal Cancer|August 16, 2011
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancerDavid R Spigel, Johanna C Bendell, Michael McCleod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2007
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasCarol Aghajanian, Howard A Burris, Suzanne Jones, et al.
Current Drug Metabolism|April 6, 2012
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancerDan Lu, Howard A Burris, Bei Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2012
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, Mark S Rubin, et al.
Cancer Investigation|July 6, 2016
A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal TumorsJohanna C Bendell, Todd M Bauer, Ruth Lamar, et al.
Breast Cancer Research and Treatment|November 29, 2023
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancerErica L Mayer, Nabihah Tayob, Siyang Ren, et al.
The Oncologist|October 29, 2002
A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignanciesSuzanne F Jones, F Anthony Greco, John D Hainsworth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignanciesHoward A Burris, Charles W Taylor, Suzanne F Jones, et al.
Clinical Genitourinary Cancer|February 15, 2008
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trialJohn D Hainsworth, David R Spigel, Jeffrey A Sosman, et al.
Clinical Breast Cancer|January 15, 2020
A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast CancerDenise A Yardley, William Liggett, Mark Mainwaring, et al.
Pageof 25